Apixaban Accord 2,5 mg or 5 mg Tablet
PDF Leaflet Revision Date: 03 October 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Prevention of VTE and stroke in NVAF patients.
Dosage (summary)
2.5 mg twice daily for VTE prevention; 5 mg twice daily for NVAF.
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly
Pregnancy & Breastfeeding
Not recommended during pregnancy; unknown if excreted in breast milk.
Key Drug Interactions
- Strong CYP3A4 and P-gp inhibitors
- Strong CYP3A4 and P-gp inducers
- Anticoagulants
Contraindications
- Hypersensitivity
- Active bleeding
- Severe renal disease
- Severe hepatic disease
Common side effects
- Anaemia
- Haemorrhage
- Contusion
- Epistaxis
- Haematoma
Counselling Points
- Take with or without food
- Monitor for signs of bleeding
- Discontinue before surgery
Serious warnings
- Risk of bleeding
- No reversal agent available
- Caution in neuraxial procedures
Important Disclaimer
The Apixaban Accord 2,5 mg or 5 mg Tablet professional information leaflet below is the property of Accord Healthcare and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
